> Details

Oliveira, Mafalda; Navarro, Alejandro; De Mattos-Arruda, Leticia; Sánchez-Ollé, Gessamí; Bellet, Meritxell; Balmaña, Judith; Gómez-Pardo, Patricia; Perez-Garcia, Jose Manuel; Muñoz-Couselo, Eva; Vidal, Maria; Ortega, Vanessa; Dienstmann, Rodrigo; Aura, Claudia; Prudkin, Ludmilla; Vivancos, Ana; Rodon Ahnert, Jordi; Baselga, José; Tabernero, Josep; Cortes, Javier; Saura, Cristina

PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts)

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts)
  • Contributor: Oliveira, Mafalda; Navarro, Alejandro; De Mattos-Arruda, Leticia; Sánchez-Ollé, Gessamí; Bellet, Meritxell; Balmaña, Judith; Gómez-Pardo, Patricia; Perez-Garcia, Jose Manuel; Muñoz-Couselo, Eva; Vidal, Maria; Ortega, Vanessa; Dienstmann, Rodrigo; Aura, Claudia; Prudkin, Ludmilla; Vivancos, Ana; Rodon Ahnert, Jordi; Baselga, José; Tabernero, Josep; Cortes, Javier; Saura, Cristina
  • Published: American Society of Clinical Oncology (ASCO), 2012
  • Published in: Journal of Clinical Oncology, 30 (2012) 15_suppl, Seite 509-509
  • Language: English
  • DOI: 10.1200/jco.2012.30.15_suppl.509
  • ISSN: 1527-7755; 0732-183X
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: 509 Background: The role of PI3Kp dysregulation as a predictor of sensitivity to PI3Kpi is unclear. We aimed to evaluate the efficacy of PI3Kpi in two cohorts of MBC pts with assessable PI3Kp status. Methods: MBC pts treated in ≥3rd line with PI3Kpi were reviewed. PI3Kp status: (a) No dysregulation: PIK3CA wt and PTEN normal; (b) PI3Kp dysregulation: PIK3CA mutation (PIK3CAmut) or PTEN low (HScore≤50). Cohort A: pts treated with single agent PI3Kpi. Cohort B: pts treated with PI3Kpi in combination with hormonal therapy (HT), chemotherapy (CT) and/or trastuzumab (T). Results: Out of 232 MBC pts screened for PI3Kp alterations from Sep09 to Sep11, 32 were treated with PI3Kpi. Cohort A (n=17): HR+/HER2- 88%, HER2+ 6%, triple negative 6%; median age 43, median MBC lines 4 (2-9); PIK3CAmut in 10/17 (58.8%; 6 exon9, 4 exon20), PTEN low 3/17 (17.6%), 1 pt both; PI3Kp dysregulation 12/17 pts. Cohort B (n=15): HR+/HER2- 40%, HER2+ 60%; median age 49, median MBC lines 4 (2-13); PIK3CAmut 3/13 assessable (23.1%; all exon20), PTEN low 6/15 (40%), 1 pt both; PI3Kp dysregulation 8/15 pts. Time to progression to PI3Kpi (TTP), overall survival from MBC diagnosis (OSMBC) and OS from PI3Kpi beginning (OSPI3Kpi), according to PIK3CA status and PI3Kp dysregulation, are shown. No differences were found according to PTEN status. Conclusions: These results suggest that the best outcomes with PI3Kpi in PIK3CAmut MBC pts occur when they are used in combination with HT/CT/T. Activity of non selective PI3Kpi used as single agents seems to be limited, making results from prospective trials with selective PI3Kα inhibitors and PI3Kpi in combinations eagerly awaited. [Table: see text]
  • Access State: Open Access